HT-6184 is under clinical development by Halia Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HT-6184’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HT-6184 overview
The drug candidate is under development for the treatment of thermal hyperalgesia and mechanical allodynia, Alzheimer’s disease, myelodysplastic syndrome (MDS), chronic inflammation, acute myeloid leukemia (AML), inflammation, pain and neuroinflammation. It acts by targeting NEK7/NLRP3. It is administered through oral route.
Halia Therapeutics overview
Halia Therapeutics (Halia) is a preclinical-stage biopharmaceutical company. It is headquartered in Lehi, Utah, the US.
For a complete picture of HT-6184’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.